Literature DB >> 18160342

Principal component analysis and discrimination of variables associated with pre- and post-natal exposure to mercury.

Rejane C Marques1, José V E Bernardi, José G Dórea, Wanderley R Bastos, Olaf Malm.   

Abstract

The variance of variables associated with neurodevelopment at 180 days, pre-natal variables (Hg in placenta, blood and hair) and post-natal Hg exposure (including Thimerosal-containing vaccines, TCV) were examined in 82 exclusively breastfed infants using principal component analysis (PCA). This multivariate method was applied to identify hierarchy and sets of interrelated variables. The PCA yielded a two-factor solution, explaining 92% of variance and summarizing most of the relevant information in the dataset matrix: the first component represented birth weight and vaccine (first doses of Hepatitis B and DTP) variability and explained 57% of variance; the second component represented a gradient of neurodevelopment (Gesell scores) and explained 35% of variance. The third component explained only 3% of the remaining 8% variance. Beside CNS priming by breastfeeding, infant development (birth weight) and time of immunization with TCV should be considered in epidemiological studies. PCA can classify sets of variables related to vaccination and neuromotor development schedules, clearly discriminating between earlier and later TCV exposures of exclusively breastfed infants. In conclusion, the incommensurable concept of the chance of toxic risk caused by TCV-EtHg exposure against the proven benefit of immunization is in no way disputed here. However, infant neurodevelopmental (ND) disorders linked to Thimerosal-Hg stands in need of proof, but PCA points to the possibility of identifying exposure risk variables associated with ND schedules.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160342     DOI: 10.1016/j.ijheh.2007.09.008

Source DB:  PubMed          Journal:  Int J Hyg Environ Health        ISSN: 1438-4639            Impact factor:   5.840


  8 in total

Review 1.  Abating Mercury Exposure in Young Children Should Include Thimerosal-Free Vaccines.

Authors:  José G Dórea
Journal:  Neurochem Res       Date:  2017-04-24       Impact factor: 3.996

2.  Research into mercury exposure and health education in subsistence fish-eating communities of the Amazon basin: potential effects on public health policy.

Authors:  José G Dórea
Journal:  Int J Environ Res Public Health       Date:  2010-09-16       Impact factor: 3.390

Review 3.  Sources of Mercury Exposure to Children in Low- and Middle-Income Countries.

Authors:  Rita Ann Kampalath; Jennifer Ayla Jay
Journal:  J Health Pollut       Date:  2015-07-02

Review 4.  Exposure to mercury and aluminum in early life: developmental vulnerability as a modifying factor in neurologic and immunologic effects.

Authors:  José G Dórea
Journal:  Int J Environ Res Public Health       Date:  2015-01-23       Impact factor: 3.390

5.  Environmental and socio-economic determinants of infant mortality in Poland: an ecological study.

Authors:  Agnieszka Genowska; Jacek Jamiołkowski; Krystyna Szafraniec; Urszula Stepaniak; Andrzej Szpak; Andrzej Pająk
Journal:  Environ Health       Date:  2015-07-21       Impact factor: 5.984

6.  Abnormal Brain Connectivity Spectrum Disorders Following Thimerosal Administration: A Prospective Longitudinal Case-Control Assessment of Medical Records in the Vaccine Safety Datalink.

Authors:  David A Geier; Janet K Kern; Kristin G Homme; Mark R Geier
Journal:  Dose Response       Date:  2017-03-16       Impact factor: 2.658

7.  Effects of prenatal exposure to pollutants on children's development: additional issues.

Authors:  José G Dórea
Journal:  Environ Health Perspect       Date:  2008-10       Impact factor: 9.031

8.  Mitochondrial dysfunction, impaired oxidative-reduction activity, degeneration, and death in human neuronal and fetal cells induced by low-level exposure to thimerosal and other metal compounds.

Authors:  D A Geier; P G King; M R Geier
Journal:  Toxicol Environ Chem       Date:  2009-06-11       Impact factor: 1.437

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.